Compare SM & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SM | RYTM |
|---|---|---|
| Founded | 1908 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 6.2B |
| IPO Year | 1996 | 2017 |
| Metric | SM | RYTM |
|---|---|---|
| Price | $32.56 | $86.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $34.36 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 4.0M | 692.5K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,154,000,000.00 | N/A |
| Revenue This Year | $129.01 | $55.34 |
| Revenue Next Year | $6.29 | $86.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 17.24 | N/A |
| 52 Week Low | $17.45 | $60.71 |
| 52 Week High | $35.88 | $122.20 |
| Indicator | SM | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 55.98 | 44.29 |
| Support Level | $25.16 | $82.31 |
| Resistance Level | $33.25 | $90.79 |
| Average True Range (ATR) | 1.29 | 3.66 |
| MACD | -0.16 | -0.48 |
| Stochastic Oscillator | 45.35 | 7.82 |
SM Energy Co is an independent energy company engaged in the acquisition, exploration, development, and production of oil, gas, and NGLs in Texas and Utah. The Company operates in the oil and gas extraction industry, focused on exploration and production activities, onshore in the United States. Its portfolio is comprised of assets in the Midland Basin of West Texas, the Maverick Basin of South Texas, and the Uinta Basin of northeastern Utah.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.